68Ga-DOTATATE PET/CT provides information on the location of somatostatin receptor–
expressing tumors. Integrating this imaging data effectively in patient care requires the …

Abstract Background Fluorine-18-labeled SSAs have the potential to become the next-
generation tracer in SSTR-imaging in neuroendocrine tumor (NET) patients given their …

Somatostatin receptor imaging with 68Ga-DOTATATE PET/CT (DOTATATE) is increasingly
used for managing patients with neuroendocrine tumors. The objective of this study was to …

Peptide receptor scintigraphy in humans started with the in vivo demonstration of
somatostatin receptor-positive tumors in patients using a radioiodinated somatostatin …

Neuroendocrine tumors (NETs) are rare neoplasms, which are characterized by the
presence of neuroamine uptake mechanisms and/or peptide receptors at the cell membrane …

Purpose The aim of this study was to evaluate the impact of 68 Ga-labelled DOTA 0-
lanreotide (68 Ga-DOTA-LAN) on the diagnostic assessment of neuroendocrine tumour …

Neuroendocrine tumors (NETs) can be visualized using radiolabeled somatostatin analogs.
We have previously shown the clinical potential of 64Cu-DOTATATE in a small first-in …

Neuroendocrine tumors (NETs) are uncommon malignancies of increasing incidence and
prevalence. As these slow growing tumors usually overexpress somatostatin receptors …

More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept
of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors …

The trend to inform personalized molecular radiotherapy with molecular imaging
diagnostics, a concept referred to as theranostics, has transformed the field of nuclear …